Breaking News
June 21, 2018 - People with severe obesity constantly try to reduce or control their weight
June 21, 2018 - Recovery and Treatment | NIH MedlinePlus the Magazine
June 21, 2018 - ‘Hidden’ driver discovered that helps prime the anti-tumor immune response
June 21, 2018 - Groundbreaking discovery could be key to preventing cancer metastasis
June 21, 2018 - Impulse control disorders found to be more common in people taking Parkinson’s drugs
June 21, 2018 - Study finds possible link between Type 2 diabetes and common white pigment
June 21, 2018 - Most emergency department patients wish to be involved in medical decision-making
June 21, 2018 - Study highlights growing problem of ‘iPad neck’ among young adults and women
June 21, 2018 - UT Southwestern scientists identify gene mutation linked with perplexing brain condition
June 21, 2018 - New study sheds light on role of vitamin D in healthy pregnancy
June 21, 2018 - Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache
June 21, 2018 - Unlocking the secrets of HIV’s persistence
June 21, 2018 - New guidelines recommend newborns with Down’s syndrome to receive leukemia test
June 21, 2018 - BetterYou’s new Magnesium Bone Lotion helps maximize bone health
June 21, 2018 - UH scientist receives grant to examine understudied part of glaucoma
June 21, 2018 - Lifestyle intervention could normalize unhealthy behaviors that lead to cancer, chronic disease
June 21, 2018 - Combining two anti-malarial vaccines could greatly reduce number of infections
June 21, 2018 - By 2030, prostate and lung cancers expected to be most common cancers among HIV population
June 21, 2018 - Researchers evaluate patient satisfaction and well-being after breast reconstruction
June 21, 2018 - Combining stem cell technology and artificial intelligence to diagnose genetic cardiac diseases
June 21, 2018 - Monash study reveals why older people have reduced immune responses to cancer therapy
June 21, 2018 - Researchers develop new microscope system that can image living tissue in real time
June 21, 2018 - Long-term estrogen therapy alters microbial composition and activity in the gut
June 21, 2018 - Study points to dangers of feeding non-dairy drink to infants
June 21, 2018 - Cannabis Use Linked to Psychosis Symptoms in Adolescents
June 21, 2018 - Inadequate sleep could cost countries billions
June 21, 2018 - Inhibiting epigenetic proteins with drugs could prevent development of breast cancer
June 21, 2018 - Study identifies factors that contribute to vaginal dryness
June 21, 2018 - Researchers employ nucleotide-based gene silencing to mitigate common ataxia
June 21, 2018 - New tool determines best treatment plan for adults with severe asthma
June 21, 2018 - Identifying gene variants that contribute to ovarian reserve may improve female fertility
June 21, 2018 - Religious involvement has no significant effect on misuse of prescription opioids, study finds
June 21, 2018 - Researchers characterize key signaling network that drives growth of triple negative breast cancers
June 21, 2018 - AHA: Big Weight Gain in 1st Pregnancy Could Boost Preeclampsia Risk
June 21, 2018 - How vaping helps even hardened smokers quit
June 21, 2018 - Gaming disorder an official disease condition says WHO
June 21, 2018 - Oxygen consumption in human BAT increases after a meal, shows research
June 21, 2018 - Research finds addictions to be diseases of the brain, not criminal behavior or personality disorders
June 21, 2018 - New study is testing safety and efficacy of glycoside in breaking up kidney stones
June 21, 2018 - Biosimilar competition may offer hope for cheaper, better psoriasis treatments in the future
June 21, 2018 - Cells form cage-like structures that trap viruses
June 21, 2018 - Wound protector use linked to significant reduction in surgical site infection
June 21, 2018 - African Americans and Latinos are more likely to be at risk for depression than Whites
June 21, 2018 - Genome study presents new way to track historical demographics of US populations
June 20, 2018 - Study sheds light on the early stages of tumorigenesis
June 20, 2018 - Quick adoption of new diagnostic tests could help NHS to save nearly £7 billion
June 20, 2018 - Mayo Clinic researchers find genetic mutations that increase person’s risk for pancreatic cancer
June 20, 2018 - Chemists invent new method for remote chiral induction
June 20, 2018 - Methadone or buprenorphine associated with reductions in opioid related mortality
June 20, 2018 - New simulation approach predicts efficacy of HIV-prophylaxis medications
June 20, 2018 - Rhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Rare Genetic Disorders of Obesity
June 20, 2018 - Threat of malaria left its mark on the immune system in people with African ancestry
June 20, 2018 - Recent-onset type 2 diabetes may be early expression of pancreatic cancer
June 20, 2018 - Why are vaccines less effective in the developing world?
June 20, 2018 - Study opens new window into cellular events that occur in the brain during absence seizures
June 20, 2018 - Humana and Walgreens to provide easier access to primary care and other services for seniors
June 20, 2018 - ANU research could help find life in Mars and other planets
June 20, 2018 - Multidisciplinary Human-Focused Research
June 20, 2018 - ‘Mind-minded’ parents contribute greatly to development of infants’ emotion regulation capacity
June 20, 2018 - New study finds increase in use of alternative medicines among children
June 20, 2018 - Forgetting plays a positive role in learning, research suggests
June 20, 2018 - Elevated NT-proBNP Found to Up Cardiovascular Risk in T2DM
June 20, 2018 - Genetics Home Reference: White-Sutton syndrome
June 20, 2018 - Canadian team reports success in transplanting hepatitis C organs
June 20, 2018 - Separating migrant children from parents at US border tantamount to child abuse
June 20, 2018 - Study finds more information about how gene linked to ASD affects the brain
June 20, 2018 - Researchers develop portable monitor to detect dangerous drop in white blood cells
June 20, 2018 - Floppy eyelids linked to sleep apnea
June 20, 2018 - Can-Fite provides update on Phase II clinical trial with drug candidate Namodenoson
June 20, 2018 - KIYATEC enrolls first patients with solid tumors in clinical study of its EV3D drug response assay
June 20, 2018 - Study finds growing support to allow pharmacists to write prescriptions
June 20, 2018 - Malnutrition could have major health implications on patients’ surgical outcomes, shows research
June 20, 2018 - LabConnect collaborates with Symphony to support clinical research industry
June 20, 2018 - Italian innovative SME receives 2.5 million Euro from RedSeed Ventures
June 20, 2018 - AHA: Kids Can Drown Quickly and Silently, So Prevention Is Key
June 20, 2018 - Continuous glucose monitors proven cost-effective, add to quality of life for diabetics
June 20, 2018 - Researchers use droplet-sized ‘miniecosystems’ to test therapeutic potential of molecules
June 20, 2018 - New approach could provide objective and easy-to-obtain measure of dietary adherence
June 20, 2018 - Dual-therapy approach can help boost motor recovery in stroke victims
June 20, 2018 - ‘Miracle treatment’ long-term success for babies with diabetes
Genentech Announces FDA Approval for Venclexta Plus Rituxan for People With Previously Treated Chronic Lymphocytic Leukemia

Genentech Announces FDA Approval for Venclexta Plus Rituxan for People With Previously Treated Chronic Lymphocytic Leukemia

image_pdfDownload PDFimage_print

South San Francisco, CA — June 8, 2018 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Venclexta (venetoclax) in combination with Rituxan (rituximab) for the treatment of people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Venclexta is being developed by AbbVie and Genentech, a member of the Roche Group. It is jointly commercialized by the companies in the United States and commercialized by AbbVie outside of the United States.

“We are pleased that this approval makes Venclexta, a first-of-its-kind targeted therapy, available for more people with chronic lymphocytic leukemia whose disease has returned after previous treatment,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “Venclexta plus Rituxan provides a new chemotherapy-free option shown to help people live longer without their disease progressing compared to a standard-of-care therapy.”

The approval of Venclexta plus Rituxan for people with previously treated CLL is primarily based on the results of the Phase III MURANO study, which were published online in the New England Journal of Medicine in March 2018 and presented at the American Society of Hematology Annual Meeting in December 2017. The results showed that a fixed duration of treatment with Venclexta plus Rituxan significantly reduced the risk of disease progression or death (progression-free survival; PFS) by 81 percent compared with bendamustine plus Rituxan, a current standard of care (HR=0.19; 95 percent CI 0.13-0.28; p<0.0001).

The most common side effects of Venclexta in combination with Rituxan include low white blood cell count, diarrhea, upper respiratory tract infection, cough, fatigue, and nausea.

Today’s FDA approval converts Venclexta’s accelerated approval to a full approval. The FDA has also updated the indication for Venclexta as a single agent, which is now approved for the treatment of people with CLL or SLL, with or without 17p deletion, who have received at least one prior therapy. Venclexta was previously granted accelerated approval in April 2016 as a single agent for the treatment of people with CLL with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.

The supplemental New Drug Application (sNDA) based on the MURANO data was granted Priority Review, a designation given to medicines that the FDA has determined to have the potential to provide significant improvements in the treatment, prevention or diagnosis of a disease. The FDA also previously granted Breakthrough Therapy Designation for Venclexta in combination with Rituxan for the treatment of relapsed or refractory CLL. Venclexta in combination with Rituxan is recommended in the National Comprehensive Cancer Network (NCCN) guidelines as a treatment option for previously treated CLL (Category 1, Preferred).

An application for a variation of the marketing authorization based on the MURANO data has also been submitted to and validated by the European Medicines Agency (EMA). Additional submissions of the MURANO data to health authorities around the world are ongoing.

About the MURANO study

MURANO (NCT02005471) is a Phase III open-label, international, multicenter, randomized study evaluating the efficacy and safety of Venclexta in combination with Rituxan compared to bendamustine in combination with Rituxan (BR). All treatments were of fixed duration. Following a five-week dose ramp-up schedule for Venclexta, patients on the Venclexta plus Rituxan arm received six cycles of Venclexta plus Rituxan followed by Venclexta monotherapy for up to two years total. Patients on the BR arm received six cycles of BR. The study included 389 patients with chronic lymphocytic leukemia (CLL) who had been previously treated with at least one line of therapy. Patients were randomly assigned in a 1:1 ratio to receive either Venclexta plus Rituxan or BR. The primary endpoint of the study was progression-free survival (PFS). Secondary endpoints included overall survival (OS), overall response rate (ORR) and complete response rate (with or without complete blood count recovery, CR/CRi).

Common Grade 3 or higher adverse reactions occurring at least 2 percent more frequently in patients treated with Venclexta plus Rituxan vs. BR, respectively, were low white blood cell count (neutropenia, 62% vs. 44%), diarrhea (3% vs. 1%), and tumor lysis syndrome (3% vs. 1%).

About CLL/SLL

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia, and in 2018, it is estimated there will be more than 20,000 new cases of CLL diagnosed in the United States. Although signs of CLL may disappear for a period of time after initial treatment, the disease is considered incurable and many people will require additional treatment due to the return of cancerous cells.

In CLL, the cancer primarily occurs in the blood and bone marrow. Small lymphocytic lymphoma (SLL) is similar to CLL, but primarily occurs in the lymph nodes.

About Genentech Access Solutions

Access Solutions is part of Genentech’s commitment to helping people access the Genentech medicines they are prescribed, regardless of their ability to pay. The team of in-house specialists at Access Solutions is dedicated to helping people navigate the access and reimbursement process, and to providing assistance to eligible patients in the United States who are uninsured or cannot afford the out-of-pocket costs for their medicine. To date, the team has helped more than 1.5 million patients access the medicines they need. Please contact Access Solutions (866) 4ACCESS/(866) 422-2377 or visit http://www.Genentech-Access.com for more information.

About Venclexta

Venclexta is a small molecule designed to selectively bind and inhibit the BCL-2 protein, which plays an important role in a process called apoptosis (programmed cell death). Overexpression of the BCL-2 protein in CLL has been associated with resistance to certain therapies. It is believed that blocking BCL-2 may restore the signaling system that tells cells, including cancer cells, to self-destruct. Venclexta is being developed by AbbVie and Genentech, a member of the Roche Group. It is jointly commercialized by the companies in the United States and commercialized by AbbVie outside of the United States.

Together, the companies are committed to further research with Venclexta, which is currently being evaluated in Phase III clinical trials for the treatment of CLL, along with studies in several other types of cancers. In the United States, Venclexta has been granted four Breakthrough Therapy Designations by the FDA: in combination with Rituxan for people with relapsed or refractory CLL; as a monotherapy for people with relapsed or refractory CLL with 17p deletion; in combination with hypomethylating agents (azacitidine or decitabine) for people with untreated acute myeloid leukemia (AML) ineligible for intensive chemotherapy; and in combination with low-dose cytarabine (LDAC) for people with untreated AML ineligible for intensive chemotherapy.

About Genentech in Hematology

For more than 20 years, Genentech has been developing medicines with the goal to redefine treatment in hematology. Today, we’re investing more than ever in our effort to bring innovative treatment options to people with diseases of the blood. For more information visit http://www.gene.com/hematology.

About Genentech

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

Source: Genentech

Posted: June 2018

Related Articles:

Venclexta (venetoclax) FDA Approval History

Tagged with:

About author

Related Articles